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Abstract 
Inhalation therapy with small interfering RNA (siRNA) is a promising approach in the 
treatment of pulmonary disorders. However, clinical translation is severely limited by the lack 
of suitable delivery platforms. In this study, we aim to address this limitation by designing a 
novel bioinspired hybrid nanoparticle with a core-shell nanoarchitecture, consisting of a 
siRNA-loaded dextran nanogel (siNG) core and a pulmonary surfactant (Curosurf®) outer 
shell. The decoration of siNGs with a surfactant shell enhances the colloidal stability and 
prevents siRNA release in the presence of competing polyanions, which are abundantly 
present in biofluids. Additionally, the impact of the surfactant shell on the biological efficacy 
of the siNGs is determined in lung cancer cells. The presence of the surfactants substantially 
reduces the cellular uptake of siNGs. Remarkably, the lowered intracellular dose does not 
impede the gene silencing effect, suggesting a crucial role of the pulmonary surfactant in the 
intracellular processing of the nanoparticles. In order to surmount the observed reduction in 
cellular dose, folate is incorporated as a targeting ligand in the pulmonary surfactant shell to 
incite receptor-mediated endocytosis. The latter substantially enhances both cellular uptake 
and gene silencing potential, achieving efficient knockdown at siRNA concentrations in the 
low nanomolar range. 
 
1. Introduction 
 
RNA interference (RNAi) represents a powerful process that regulates gene expression in 
eukaryotic cells on the post-transcriptional level. Sequence-specific cleavage of mRNA 
transcripts via RNAi can be initiated by synthetic RNA duplexes, termed small interfering 
RNA (siRNA). Since siRNAs can be designed to repress the expression of any gene of 
interest, they are being extensively investigated for the treatment of various diseases by 
blocking the expression of disease-related proteins [1-3]. More than 20 clinical trials have 
already been conducted involving siRNA-mediated therapy. However, despite intensive 
research efforts, to date no RNAi-based therapeutic has advanced into the clinic [4, 5]. 
One of the major bottlenecks impeding its clinical translation is the lack of biocompatible 
siRNA carriers that can overcome the various extra- and intracellular barriers to deliver the 
siRNA to the target cell cytoplasm [6, 7]. To date, the most widely studied siRNA delivery 
systems include polymer-[8, 9] and lipid-based [10-12] nanoparticles. Earlier work from our 
group demonstrated the feasibility of cationic dextran nanosized hydrogels (nanogels) for 
siRNA delivery. These nanogels (NGs) encompass a high loading capacity for siRNA 
(exceeding 50 wt%), are efficiently internalized by cultured cells and are able to induce a 
marked RNAi effect in vitro [13]. 
Unfortunately, polymer- or lipid-based siRNA-loaded nanoparticles often fail to surmount the 
numerous biological barriers en route to their intracellular target in vivo. In order to address 
the multifaceted drug delivery challenges, several research groups aim to combine the unique 
strengths of both polymers and lipids within a single delivery vehicle, to obtain lipid-polymer 
nanocomposites [14-16]. Hybrid lipid-polymer nanoparticles have emerged as a robust and 
promising delivery platform for in vivo siRNA delivery upon systemic administration [17, 18]. 
However, their potential in local pulmonary applications remains largely unexplored, while 
respiratory diseases constitute a global health problem and inhalation therapy with siRNA 
nanomedicines could address the unmet therapeutic need for various pulmonary disorders [19-
21]. 
Apart from the hybrid lipid-polymer nanoparticles, there is a growing interest as well in the 
implementation of bio-inspired materials in drug delivery vehicles. These materials are 
believed to possess specific features from which drug carriers could benefit, including an 
improved in vivo stability, biocompatibility, and intrinsic cell-targeting [22, 23]. In terms of 
drug delivery to the lung, the value of pulmonary surfactants as a drug carrier as such, or in 
combination with other nanomedicines, has been suggested [24-28]. In a recent study from 
our group, natural-derived pulmonary surfactants (e.g. Curosurf®) were used as a model to 
assess the impact that pulmonary surfactant might have on the delivery potential of siRNA-
loaded NGs (siNGs) [29]. Surprisingly, these data already revealed that pulmonary surfactants 
play a crucial unknown role in the cellular processing of the siNGs in lung-specific cell types, 
resulting in an improved cytosolic delivery of the encapsulated siRNA. However, the 
approach to combine the beneficial features of both siNGs and pulmonary surfactant in a 
single delivery vehicle has not yet been evaluated. Moreover, the inclusion of a targeting 
moiety to further boost the delivery process has not been attempted to date. Therefore, the 
major aim of this work is to design a core-shell formulation consisting of siNGs endowed 
with a clinically approved pulmonary surfactant (Curosurf®) shell. Both the colloidal stability 
and the siRNA release profiles in the presence of competing polyanions, i.e. mucin and 
dextran sulfate, are evaluated. The core-shell nanoarchitecture is assessed via cryo-TEM 
imaging. Furthermore, it is investigated if the presence of the surfactant coat could enhance 
the biological efficacy of the siNGs, and if it could be employed for anchoring a targeting 
moiety to stimulate cellular uptake and further enhance siRNA delivery in lung cancer cells. 
Finally, the intracellular fate of the different nanoparticles is evaluated via confocal 
fluorescence microscopy and colocalization analysis. 
 
2. Materials and methods 
 
2.1. siRNA duplexes 
Twenty-one nucleotide siRNA duplexes targeted against Enhanced Green Fluorescent Protein 
(EGFP), hereafter abbreviated as siEGFP, and non-targeting negative control duplexes 
(siCTRL) were purchased from Eurogentec (Seraing, Belgium). SiEGFP: sense strand = 5´-
CAAGCUGACCCUGAAGUUCtt-3´; antisense strand = 5´-GAACUUCAGGGUCAGCUUG 
tt-3´. SiCTRL: sense strand = 5´-UGCGCUACGAUCGACGAUGtt-3´; antisense strand = 5´-
CAUCGUCGAUCGUAGCGCAtt-3´ (capital letters represent ribonucleotides; lower case 
letters represent 2´-deoxyribonucleotides). For fluorescence experiments, the siCTRL duplex 
was labeled with a Cy5 dye at the 5’ end of the sense strand (siCy5). The fluorescent 
modifications were performed and verified by Eurogentec. The concentration of the siRNA 
stock solutions in nuclease free water (Ambion®-Life Technologies, Ghent, Belgium) was 
calculated from absorption measurements at 260 nm (1 OD260 = 40 µg mL-1) with a Nanodrop 
2000 spectrophotometer (Thermo Fisher Scientific, DE, USA). 
 
2.2. Synthesis of dextran nanogels and loading with siRNA 
Cationic dextran nanogels were prepared using an inverse mini-emulsion photopolymerization 
method as reported previously [13]. Briefly, 65 mg of dextran hydroxyethyl methacrylate 
(dex-HEMA; degree of substitution 5.2) [30] was dissolved in a solution containing 40 µL 
irgacure 2959 (10 mg mL-1 in water; Sigma-Aldrich, Bornem, Belgium), 80 µL nuclease free 
water and 40 µL of a cationic methacrylate monomer, [2-(methacryloyloxy)-
ethyl] trimethylammonium chloride (TMAEMA, 80 wt% solution in water; Sigma-Aldrich). 
The obtained dex-HEMA solution was emulsified in 5 mL of mineral oil (Sigma-Aldrich), 
supplemented with 10 % (v/v) of the surfactant ABIL EM 90 (Evonik Goldschmidt GmbH, 
Essen, Germany), through ultrasonication (50 s, amplitude 15 %; Branson Digital Sonifier®, 
CT, USA). The formed emulsion nanodroplets were immediately crosslinked by UV 
irradiation (900 s, Bluepoint 2.1 UV source, Hönle UV technology, Gräfelfing, Germany) 
under cooling (4°C). The resulting dex-HEMA-co-TMAEMA nanogels, hereafter abbreviated 
as NGs, were collected by precipitation in acetone, and washed three times with 
acetone:hexane (1:1). Traces of organic solvent were removed by vacuum evaporation and the 
pellet was redispersed in 5 mL nuclease free water. To assure long-term stability, the NGs 
were lyophilized and stored desiccated.  
To obtain siRNA-loaded NGs (siNGs), first a NG stock (2 mg mL-1) was prepared by 
dispersing a weighed amount of lyophilized particles in ice-cooled nuclease free water, 
followed by brief sonication (amplitude 10 %). Subsequently, equal volumes of NG and 
siRNA dilutions in N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) buffer 
(pH 7.4, 20 mM) were mixed and incubated at 4 °C for ≥ 15 min to allow complexation. 
 
2.3. Preparation of pulmonary surfactant-coated nanogels 
A commercially available pulmonary surfactant, derived from minced porcine lungs 
(Curosurf®; Chiesi Pharmaceuticals, Parma, Italy), was used to construct the pulmonary 
surfactant shell. For a detailed discussion on the different lipid and protein constituents, the 
reader is referred to recent articles on this topic [31, 32]. Prior to the formation of the 
pulmonary surfactant coat, the NGs were loaded with siRNA, as described above. For the 
second step, where the siNGs interact with the pulmonary surfactant, two different protocols 
were evaluated. In the first protocol, Curosurf® (diluted in HEPES buffer) was homogenized 
using a probe sonicator to form surfactant vesicles prior to mixing with the siNGs. The hybrid 
nanoparticles obtained via this approach are further abbreviated as coated siNGs-1. In the 
alternate protocol, the unprocessed Curosurf® dispersion was first incubated with siNGs for 
10 min at 4 °C, after which the surfactant coat was formed by high-energy sonication, using a 
probe sonicator (amplitude 10 %). This resulted in a hybrid nanoparticle further denoted as 
coated siNGs-2. Depending on the experimental needs, different surfactant-to-NG weight 
ratios were used.  
To evaluate the influence of salt during the preparation of the coated siNGs-2 formulation, 
siRNA and NGs were diluted in phosphate buffered saline (PBS; Invitrogen, Merelbeke, 
Belgium). PBS has a 15-fold higher osmolality (280-315 mOsm kg-1) compared to HEPES 
buffer (20 mOsm kg-1). After 15 min incubation (4 °C), Curosurf® (diluted in PBS) was added 
to the siNGs and allowed to interact during 10 min at 4 °C. Hereafter, the surfactant coat was 
formed by high-energy sonication as described above. 
2.4. Fluorescence single particle tracking 
Fluorescence single particle tracking (fSPT) is a technique that monitors the diffusional 
movement of individual fluorescently labeled particles using a highly sensitive fluorescence 
microscope setup [33]. This technique allows to accurately measure size distributions of 
nanoparticles dispersed in complex biological fluids. In our experiments, a swept-field 
confocal microscope (LiveScan Swept Field Confocal Microscope System; Nikon, Brussels, 
Belgium) was used. Briefly, a solid-state 125 mW 640 nm (Agilent Technologies, CA, USA) 
laser was used to excite the fluorophore in samples mounted on the microscope equipped with 
a Plan Apo VC 100x 1.4 NA oil immersion objective lens (Nikon). A fast and sensitive 
EMCCD camera (Ixon Ultra 897; Andor Technology, CT, USA) enables recording high-
speed confocal movies of individual diffusing particles. Single particle trajectories, and 
corresponding diffusion coefficients, were subsequently calculated using in-house developed 
software, which is explained in detail elsewhere [34]. 
In this work, fSPT was used to compare the size distributions of siNGs and surfactant-coated 
siNGs prepared via the protocols described above. Hereto, the NGs were first loaded with 
Cy5-labeled siRNA (10 pmol siRNA per µg NGs), allowing to specifically monitor the 
movements of the fluorescent NGs without interference of the non-labeled surplus Curosurf® 
vesicles present in the dispersion. The nanoparticles were diluted in HEPES buffer (pH 7.4, 
20 mM) or in Opti-MEM® (Gibco®- Life Technologies) to give a concentration suitable for 
fSPT (typical concentrations of 108–1010 particles per mL). A total of 5 µL of these samples 
was then applied between a microscope slide and a cover glass with a double-sided adhesive 
sticker of 120 µm thickness in between (Secure-Seal Spacer, Molecular Probes, Leiden, The 
Netherlands). The microscope was always focused 20 µm above the cover glass. For each 
sample, 20 movies of approximately 200 frames each were recorded at different random 
locations within the sample, mounting to 1600-2400 individual particle trajectories per sample. 
 
2.5. Fluorescence fluctuation spectroscopy 
Fluorescence fluctuation spectroscopy (FFS) monitors fluorescence intensity fluctuations in 
the excitation volume of a confocal microscope. The fluorescence fluctuations originate from 
the movement of fluorescent molecules in and out a fixed excitation volume. FFS 
measurements were performed with a laser scanning confocal microscope (C1si, Nikon) 
equipped with a water immersion objective lens (Plan Apo 60X, NA 1.2, collar rim correction, 
Nikon), using a 637 nm laser line for the excitation of fluorescent siRNA (siCy5). The latter 
setup was combined with the detection channels of the fluorescence correlation spectrometer 
MicroTime 200 (Picoquant GmbH, Berlin, Germany), equipped with SymPhoTime software. 
In previous work by our group, FFS was used to quantify the complexation of fluorescently 
labeled siRNA to e.g. cationic liposomes or polymers [13, 35-37]. In this study, FFS 
experiments were carried out on dextran nanogels loaded with Cy5-labeled siRNA. First, the 
maximal loading capacity of the pre-formed NGs for siRNA was assessed by mixing 
increasing NG concentrations with a fixed amount of fluorescent siRNA. Next, the release of 
siRNA from the siNGs was evaluated before and after coating with Curosurf® in the presence 
of competing polyanions, i.e. dextran sulfate sodium salt (DEXS, 10 kDa, Sigma-Aldrich) or 
mucin (from porcine stomach-type II, Sigma-Aldrich). Equal volumes of these strongly 
negatively charged polymers (in HEPES buffer or PBS) were mixed with the nanoparticles, 
resulting in a final siRNA concentration of 25 nM. After 10 min incubation at room 
temperature the samples were transferred to a glass-bottomed 96-well plate (Greiner Bio-one 
GmbH, Frickenhausen, Germany). Subsequently, the focal volume of the microscope was 
positioned in the sample and the fluorescence fluctuations were recorded during a 60 s time 
interval. All samples were prepared in triplicate. The average fluorescence intensity of freely 
diffusing and complexed siRNA in the fluorescence fluctuation profile was determined as 
described previously [37]. 
 
2.6. Cryogenic transmission electron microscopy 
Cryogenic transmission electron microscopy (cryo-TEM) is a valuable tool for the structural 
investigation of nanosized particles [38]. Both NGs and Curosurf® vesicles were diluted in 
HEPES buffer (final concentration of respectively 5 and 10 mg mL-1). The Curosurf® vesicles 
were formed by sonication of the crude surfactant dispersion using a probe sonicator 
(amplitude 10 %; Branson). Coated nanogels were formed according to the method described 
above. The ratio of surfactant to NGs equaled 7.5 mg Curosurf® / mg NGs. 2.5 µL of the 
different samples was placed on a glow discharged holey carbon coated grid (Quantifoil® R 
3.5/1, Quantifoil Micro Tools GmbH, Grosslöbichau, Germany). The excess of liquid was 
blotted with a filter paper, reducing the droplet to a thin film. The samples were vitrified in 
liquid ethane, using a vitrobot (FEI, Eindhoven, The Netherlands) and stored in liquid 
nitrogen until observation. The grids were transferred to a cryo specimen holder type 626 
(Gatan GmbH, München, Germany) and observed in a CM 120 cryo-electron microscope 
(Philips, Eindhoven, The Netherlands) operating at 120 keV. Images were recorded on a 
slow-scan CCD camera (Gatan GmbH) under low-dose conditions. 
 
2.7. Preparation of folate-targeted surfactant-coated nanogels 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] 
 (ammonium salt) (DSPE-PEG2000-folate) was purchased from Avanti Polar Lipids, Inc. (AL, 
USA). To incorporate folate as a targeting ligand in the pulmonary surfactant layer, Curosurf® 
and DSPE-PEG2000-folate were mixed in chloroform:methanol (2:1) at different weight ratios. 
A lipid film was formed by rotary evaporation of the organic solvents under vacuum at 37 °C. 
The dried lipid film was rehydrated in HEPES buffer under mechanical agitation, resulting in 
a final lipid concentration of 4.5 mg mL-1. This hydrated lipid film was used in the coating 
procedure, as described above. To assess the influence of DSPE-PEG2000-folate on the particle 
size, size distribution of the hybrid nanoparticle upon inclusion of the folate ligands was 
determined in HEPES buffer using fSPT. Additionally, siRNA release profiles in HEPES or 
mucin were quantified by FFS. 
 
2.8. Cell lines and culture conditions 
Cell culture experiments were performed using human alveolar epithelial cells (H1299), 
H1299 cells that stably express the EGFP (H1299_EGFP), and human lung adenocarcinoma 
cells (A549). H1299 and A549 cells were cultured in RPMI 1640 and DMEM, respectively, 
supplemented with 2 mM glutamine, 10 % fetal bovine serum and 100 U mL-1 
penicillin/streptomycin at 37°C in a humidified atmosphere containing 5 % CO2. Cells were 
passed every 3 days using 0.25 % trypsin- ethylenediaminetetraacetic acid solution in order to 
maintain sub-confluency. H1299_EGFP cells were treated with medium containing 1 mg mL-
1 Geneticin® once per month for selection. All materials were purchased from Gibco®-Life 
Technologies, except for the serum, which was delivered by HycloneTM (Thermo Fisher 
Scientific). 
 
2.9. Quantification of siRNA cellular internalization by flow cytometry 
To quantify the cellular uptake of siRNA by flow cytometry in the lung epithelial cells, 
H1299_EGFP and A549 cells were seeded in 24-well plates (Greiner Bio-One GmbH) at a 
density of 1.85 x 104 cells cm-2 and 2.10 x 104 cells cm-2 respectively. After 24 h, the cells 
were incubated for 4 h (37 °C, 5 % CO2) with the different formulations described below.  
NGs were loaded with different amounts of siRNA, labeled with 0.75 mol% Cy5 and coated 
with Curosurf® using the coating procedure described above. According to the experimental 
needs, different weight ratios of DSPE-PEG2000-folate were incorporated in the pulmonary 
surfactant, before initiating the coating procedure. After five-fold dilution in Opti-MEM®, 
resulting in a final NG concentration of 30 µg mL-1, the samples were incubated with the cells. 
Following incubation, the cells were washed with PBS supplemented with DEXS (0.1 mg 
mL-1 in PBS) to remove surface-bound fluorescence. Next, the cells were harvested in 250 µL 
flow buffer (PBS supplemented with 1 % bovine serum albumin and 0.1 % sodium azide) and 
placed on ice until flow cytometric analysis. Transfections were performed in triplicate and a 
minimum of 104 cells was analyzed in each measurement, using a FACSCaliburTM flow 
cytometer (BD Biosciences, Erembodegem, Belgium). The fluorescence detector for Cy5-
labeled siRNA detects wavelengths of 661 nm (±16 nm). Data analysis was performed using 
the CellQuest ProTM analysis software (BD Biosciences). 
 
2.10. Quantification of EGFP silencing by flow cytometry 
H1299_EGFP cells were plated in 24-well plates (1.85 x 104 cells cm-2). NGs were loaded 
with variable amounts of siCTRL or siEGFP. Next, the siNGs were coated with Curosurf®. 
Depending on the experimental needs, different weight ratios of DSPE-PEG2000-folate were 
incorporated in the pulmonary surfactant layer. After five-fold dilution in Opti-MEM®, the 
samples were brought onto the cells. Following 4 h of incubation at 37 °C and 5 % CO2, non-
internalized nanoparticles were removed and the cells were incubated with 1 mL fresh cell 
culture medium for 48 h. Cells were prepared for analysis by flow cytometry as described 
above. Transfections were performed in triplicate and a minimum of 104 cells was analyzed in 
each measurement. 
 
2.11. Visualization of lysosomal colocalization by confocal microscopy 
H1299 cells were seeded in a 35 mm culture dish (Greiner Bio-One GmbH ) at a density of 
2.0 x 104 cells cm-2 and allowed to attach overnight. The cells were incubated with NGs, 
coated NGs-2, or coated NGs-2 folate (incorporating 7.5 wt% folate in the outer surfactant 
shell) complexed with fluorescent siRNA (siCy5; 10 pmol siCy5 per µg NG) during 2 h. 
Subsequently, the cells were washed with PBS and incubated in preheated culture medium 
during 1 h. Prior to lysosomal staining, the cells were fixed (4 % paraformaldehyde in PBS) 
and permeabilized (0.5 % Tween 20 in PBS) at room temperature. After three washing steps 
with blocking buffer (5 % goat serum in PBS), the cells were incubated with a primary 
antibody against lysosomal-associated membrane protein-1 (LAMP-1; Sigma-Aldrich). After 
incubation with the secondary antibody (Alexa Fluor® 488 labeled goat anti-rabbit IgG; Life 
Technologies), cell nuclei were stained with Hoechst (Life Technologies) and the cells were 
mounted with Vectashield® Mounting Medium (Vector Labs, Peterborough, United 
Kingdom). The intracellular fluorescence distribution was visualized with a laser scanning 
confocal microscope (C1si, Nikon). The confocal images were captured with a Nikon Plan 
Apo 60x oil immersion objective using a 488 nm and 637 nm laser line for the excitation of 
Alexa Fluor® 488-labeled lysosomes and the Cy5-labeled siRNA respectively.  
An object-based colocalization algorithm was used to quantify the number of siRNA-loaded 
particles that are located inside lysosomes. First, the siCy5 loaded particles were identified in 
the red image by intensity thresholding. Only “objects” consisting of at least 8 pixels were 
retained. The thresholded image was then binarized in order to generate a mask for 
superposition on the corresponding green image (containing the Alexa Fluor®488
 
stained 
lysosomes). This allows to calculate the green (lysosomal) intensity G for each object. Next, 
the background intensity (mean value BG and standard deviation S) of the cell in the image 
was determined within a rectangular area not containing any lysosomes. Finally, a siCy5-
loaded particle is decided to be colocalized with a lysosome if its green intensity G > BG+S. 
 
2.12. Statistical analysis 
All data are presented as mean ± standard deviation (n=3). Statistical analyses were 
performed by one-way ANOVA with Bonferroni correction or by an unpaired t-test, using 
GraphPad Prism software version 6. 
 
3. Results 
 
3.1. Optimizing the protocols for the development of pulmonary surfactant-coated nanogels 
The key objective of this study was to design bio-inspired hybrid nanoparticles for pulmonary 
siRNA delivery, capable of overcoming lung-specific barriers. We envisioned core-shell 
nanocomposites, consisting of a cationic biodegradable dextran nanogel (NG) core that is 
loaded with siRNA (siRNA-loaded NG; siNG) and layered with a pulmonary surfactant shell. 
The cationic NG core was produced via an inverse mini-emulsion photopolymerization of 
methacrylated dextran and a methacrylated monomer containing a quaternary amine moiety 
[13]. A commercially available pulmonary surfactant, derived from minced porcine lungs (i.e. 
Curosurf®), was used to construct the surfactant shell. The pulmonary surfactant-coated 
siNGs (coated siNGs) were fabricated via two distinct protocols, which are depicted in Figure 
1. Both protocols encompass a two-step synthesis, wherein the first step involves the 
encapsulation of siRNA into the NGs based on electrostatic interaction, as described earlier 
by Raemdonck et al. [13]. Figure S1 shows that the NGs used in this study exhibit a high 
loading capacity for siRNA exceeding 30 pmol siRNA per µg NGs. This corresponds to ≥ 50 
wt% loading and corroborates earlier findings [13]. In order to ensure complete complexation 
of siRNA, a siRNA loading of < 20 pmol µg-1 was employed. The second step, in which the 
pulmonary surfactant is layered around the siNG core, can be achieved using two different 
mixing methods. One approach is to initially homogenize the original pulmonary surfactant 
dispersion, comprising micron-sized lipid aggregates, by probe sonication to form unilamellar 
anionic surfactant vesicles with a hydrodynamic diameter and zeta-potential of ~ 80 nm and 
~ -35 mV, respectively (data not shown). Next, the cationic siNGs and the anionic surfactant 
vesicles are combined, resulting in the electrostatic adsorption of the surfactant vesicles on the 
NG surface. The obtained dispersion of hybrid nanoparticles via this approach is hereafter 
abbreviated as coated siNGs-1 (Figure 1a). In the alternate approach, the pre-formed siNGs 
are directly mixed with the crude pulmonary surfactant dispersion, after which probe 
sonication is applied. The high-energy input in this step may facilitate lipid reorganization 
around the NG surface, resulting in a composite nanoparticle further denoted as coated siNGs-
2 (Figure 1b). 
 
3.2. The pulmonary surfactant shell enhances the colloidal stability of the siRNA-loaded 
nanogels 
The influence of both coating procedures on the size of the resultant composite formulations 
was determined. It is important to note that the preparation protocol of the surfactant-coated 
siNGs requires an excess of pulmonary surfactant to avoid aggregation. However, the latter 
implies that two distinct nanoparticle populations are likely present in the pulmonary 
surfactant-coated siNG dispersion: (i) the coated siNGs, and (ii) an excess of empty surfactant 
vesicles. The surplus of surfactant vesicles will interfere with the size determination of the 
coated siNGs when using conventional techniques based on light scattering. Unlike these 
methods, fluorescence single particle tracking (fSPT) allows to measure an accurate size 
distribution of fluorescently labeled nanoparticles in complex heterogeneous mixtures [33]. 
  
Figure 1. Scheme illustrating the synthesis of pulmonary surfactant-coated siRNA-loaded nanogels 
(coated siNGs). Two distinct protocols were evaluated of which the different steps are shown. (a) First approach 
showing (1) the formation of unilamellar surfactant vesicles by probe sonication and (2) the electrostatic 
interaction between the pre-formed siNGs and the surfactant vesicles. (b) Second approach showing (1’) the 
interaction between the pre-formed siNGs and the unprocessed surfactant dispersion and (2’) the induction of 
phospholipid fusion onto the nanogel surface via probe sonication. 
 
This technique, developed by our group, was used to determine the size of the coated siNGs. 
The NG core was loaded with fluorescently labeled siRNA (siCy5), allowing to specifically 
determine the size distribution of the coated siNGs without interference of the excess non-
labeled surfactant vesicles present in the dispersion (Figure 2).  
The uncoated siNGs have an average hydrodynamic diameter around 200 nm as measured in 
HEPES buffer (Figure 2a). The interaction of the siNGs with Curosurf® vesicles (coated 
siNGs-1), resulted in a two-fold increase in size. In contrast, the hybrid nanoparticles that 
were fabricated via the alternate protocol (coated siNGs-2) have an average size of 230 nm. 
The size distributions shown in Figure 2a were measured in a low salt buffer. As the presence 
of salt can have an important impact on the physicochemical characteristics of charged 
nanoparticles, it is crucial to also evaluate their size in isotonic media. Figure 2b shows the 
size distribution of the different formulations in Opti-MEM®. The hydrodynamic size of the 
uncoated siNGs was markedly shifted to larger values, which is indicative of aggregation. 
This observation is in stark contrast to both surfactant-coated formulations, of which the 
average size remains largely unaffected. 
 
Figure 2. Size distributions of the uncoated siRNA-loaded nanogels (siNGs) and the surfactant-coated 
siNGs, as determined by fluorescence single particle tracking. The nanogels (NGs) were loaded with 10 pmol 
of fluorescently labeled siRNA (siCy5) per µg NGs. The experiments were performed at room temperature in 
HEPES buffer (pH 7.4, 20mM) (a) or Opti-MEM® (b). 
 
3.3. The pulmonary surfactant shell prevents premature release of siRNA from the nanogel 
core 
Nanocarriers relying on electrostatic complexation for siRNA loading are particularly prone 
to dissociation of siRNA from the carrier following interaction with other polyanionic 
molecules, resulting in premature siRNA release in the extracellular matrix prior to reaching 
the intracellular site-of-action [35, 39]. The siRNA release profiles in the presence of 
competing polyanions should therefore be investigated. Here, the strongly negatively charged 
polymers dextran sulfate (DEXS) and mucin were used. The influence of the pulmonary 
surfactant shell on the release of siRNA from the NG core was assessed upon 10 min of 
incubation with these polyanions, using fluorescence fluctuation spectroscopy (FFS). The 
feasibility of FFS to quantify siRNA complexation and release has already been demonstrated 
by our group for various types of nanocarriers [35-37].  
Figure 3a indicates that mucin, starting from 0.5 mg mL-1, caused an almost complete release 
of the siRNA from the uncoated siNGs. Likewise, complexed siRNA was also fully released 
from the coated siNGs-1 formulation. In contrast, coated siNGs-2 could partially prevent the 
siRNA release, reaching a maximal release of 55 ± 2% in the presence of 1 mg mL-1 mucin. 
Increasing the sonication time in the synthesis protocol did not confer additional protection 
against siRNA release (Figure S2). On the other hand, increasing the siRNA loading of the 
NGs up to 20 pmol siRNA per µg NG resulted in an added release of siRNA from the coated 
siNGs-2 (Figure S2). Based on these results, further experiments were performed with the 
coated siNGs-2 formulation with ≤ 10 pmol siRNA loading per µg NG.  
Next, the impact of the surfactant-to-NG ratio on the siRNA release from the coated siNGs-2 
was determined. As can be seen in Figure 3b, no significant siRNA release could be detected 
prior to the addition of the competing polyanions. This implies that the decoration of the 
siNGs with the negatively charged pulmonary surfactant shell did not significantly induce a 
siRNA release, even at high weight excess of the surfactant. As expected, the siRNA was 
almost completely released from the uncoated siNGs in the presence of two destabilizing 
polyanions, i.e. mucin or DEXS (Figure 3b). Strikingly, applying a 5-fold weight excess of 
surfactant during the coating procedure could already reduce the siRNA release to maximally 
58 ± 4% or 48 ±7% in the presence of DEXS or mucin, respectively. When further increasing 
the surfactant-to-NG ratio up to a 15-fold weight excess of surfactant, the protection against 
siRNA release was significantly improved. Here, siRNA release was limited to 52 ± 4% or 33 
± 4% in the presence of DEXS or mucin, respectively. A ratio of 15 mg surfactant per mg NG 
was therefore selected for subsequent experiments.  
Likely, the presence of salt during the coating procedure could also have a significant impact 
on the structure of the surfactant shell. In Figure 3c it was confirmed that mixing pulmonary 
surfactant and siNGs in medium with low ionic strength (HEPES buffer) confers improved 
resistance against siRNA displacement by a destabilizing agent (i.e. mucin). However, 
preparing the coated siNGs in media with higher ionic strength (PBS) resulted in a complete 
release of siRNA following the addition of 2.5 mg mL-1 mucin. This can most likely be 
attributed to a charge screening effect in media with higher ionic strength, reducing the 
electrostatic interaction between the cationic siNGs and the anionic surfactants, which is 
clearly the driving force behind the lipid coating process. 
Figure 3. Influence of the pulmonary surfactant shell on the siRNA release in the presence of competing 
polyanions, as measured by fluorescence fluctuation spectroscopy. (a) Comparison of the siRNA release 
from the uncoated siRNA-loaded NGs (siNGs) or surfactant-coated siNGs (15 mg surfactant per mg NG) at 
varying concentrations of mucin in HEPES buffer (pH 7.4, 20mM). (b) siRNA release from coated siNGs-2 in 
HEPES buffer (black bars), and in the presence of dextran sulfate (2.5 mg mL-1; white bars), or mucin (2.5 mg 
mL-1; gray bars). (c) Release of siRNA from the uncoated siNGs and coated siNGs-2 (15 mg surfactant per 
mg NG) prepared in HEPES buffer (black bars) or prepared in PBS (white bars). The percentage released 
siRNA was determined in the presence of mucin (2.5 mg mL-1 in HEPES buffer or PBS, respectively). The 
concentration of fluorescent siRNA equaled 25 nM in all samples. Nanogels (NGs) were loaded with 10 pmol 
siRNA per µg NGs. Data points represent mean ± standard deviation (n=3, * p ≤ 0.05, ** p ≤ 0.01) 
 
3.4. Investigating the morphology of the pulmonary surfactant-coated nanogels 
Cryogenic transmission electron microscopy (cryo-TEM) was used to visualize the 
morphology of the composite nanoparticles. The cryo-TEM images of the uncoated siNGs 
display spherical particles with a clear porous structure and a diameter between 100 and 
200 nm (Figure 4a), which is in line with the hydrodynamic diameter measured by fSPT. 
Curosurf® vesicles appear as unilamellar and spherical liposomes with a faceted surface, 
which is attributed to the high content of dipalmitoylphosphatidylcholine (DPPC) in the 
Curosurf® formulation (Figure 4b) [40]. 
As expected based on the excess of pulmonary surfactant used in the synthesis protocol, cryo-
TEM imaging of the coated siNGs-2 dispersion revealed two co-existing nanostructures. In 
addition to the coated siNGs-2, which show a core-shell nanoarchitecture comprising the NG 
core enveloped by a unilamellar surfactant shell (Figure 4c, marked by the white arrows), 
also an excess of empty Curosurf® vesicles can be observed. It is important to note that in the 
dispersion of coated siNGs-2, every detected siNG particle appeared to be decorated with a 
surfactant outer shell. However, some nanoparticles clearly showed defects in the surrounding 
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3.6. Incorporation of a targeting ligand enhances the efficacy of the pulmonary surfactant-
coated nanogels 
Besides stabilizing the nanocarrier in the extracellular compartment and guiding intracellular 
siRNA delivery, the surfactant shell may impart other valuable traits, such as the 
straightforward inclusion of targeting ligands. One of the most extensively studied targeting 
moieties for drug delivery is folate. The folate receptor α (FR) is frequently overexpressed in 
a range of tumor cells [41]. Folate specifically binds to FR with a high affinity, making it a 
prime candidate for active targeting of nanoparticles. In our work, DSPE-PEG2000-folate, a 
PEGylated lipid carrying a folate group at its distal end, was incorporated in the pulmonary 
surfactant layer at different weight ratios (Figure 6a). First, we evaluated whether the 
incorporation of DSPE-PEG2000-folate influences the size of the hybrid nanoparticles. 
Incorporation of 10 wt% DSPE-PEG2000-folate only caused a minor shift in size distribution 
(Figure S5_a), most likely attributed to the presence of PEG chains on the particle surface. 
Likewise, the extent of siRNA release in the presence of mucin was largely independent of 
the inclusion of the folate-modified lipids (Figure S5_b). From these data we can conclude 
that the addition of up to 10 wt% of PEGylated and folate-modified lipids in the surfactant 
shell does not alter the physicochemical characteristics of the hybrid formulation. 
Before the impact of the folate targeting ligand on the cellular uptake of the coated 
nanoparticles was assessed, it was confirmed that the incorporation of folate in the outer 
surfactant shell did not induce acute cytotoxicity (Figure S4). Figure 6b shows a gradual 
increase of internalized siRNA in H1299_EGFP cells, which overexpress the FR, as a 
function of the surface density of folate groups. Remarkably, a sudden rise in cellular siRNA 
dose was observed from 5 to 7.5 wt% DSPE-PEG2000-folate with no further improvement in 
cellular uptake at 10 wt% of folate modified lipids. 
To demonstrate the specificity of the folate targeting, the cellular uptake of the different 
formulations was quantified in A549 cells, which do not overexpress the folate receptor 
(Figure 6c) [41]. The uncoated siNGs were equally well internalized by A549 cells as 
compared to H1299_EGFP cells. In addition, coating the siNGs with pulmonary surfactant 
also substantially impaired cellular uptake in A549 cells, reducing the intracellular siRNA 
dose with > 85%. Importantly, only a negligible increase in siRNA fluorescence could be 
detected in A549 cells with the optimized folate-targeted core-shell formulation. This is in 
stark contrast to the four-fold induction in intracellular siRNA fluorescence obtained in 
H1299_EGFP cells with the same formulation, confirming the involvement of a specific 
receptor-mediated uptake mechanism. To evaluate if the enhanced cellular internalization also 
results in an improved RNAi effect, we quantified the EGFP gene silencing in H1299_EGFP 
cells obtained with coated siNGs-2 as a function of wt% DSPE-PEG2000-folate inclusion 
(Figure 6d). The magnitude of EGFP silencing is markedly enhanced for the targeted 
formulations and clearly correlates with the observed improvement in cellular uptake (Figure 
6b). Incorporating 7.5 wt% DSPE-PEG2000-folate in the surfactant shell reduced EGFP 
expression with 80 % at a low siRNA concentration of 5 nM, compared to only ~20% 
silencing obtained without the folate targeting ligand. Increasing the fraction of folate-
modified lipids to 10 wt% did not further enhance the gene knockdown, which is also in line 
with the cellular uptake data. 
 
Figure 6. Influence of the folate targeting ligand on the cellular uptake and gene silencing potential of the 
hybrid nanoparticles. (a) Schematic representation of the surfactant-coated siRNA-loaded nanogels (coated 
siNGs-2) incorporating folate-modified phospholipids in the pulmonary surfactant outer shell. (b) Cellular 
uptake in H1299_EGFP cells, which overexpress the folate receptor α (FR), of coated siRNA-loaded nanogels 
(coated siNGs-2) as a function of the weight ratio of DSPE-PEG2000-folate. (c) Cellular uptake of uncoated 
siNGs, coated siNGs-2 and coated siNGs-2 incorporating 7.5 wt% folate in A549 cells, which do not 
overexpress FR. (d) Evaluation of EGFP silencing by coated siNGs-2 incorporating different folate weight ratios 
in H1299_EGFP cells. The NGs were loaded with control siRNA (siCTRL) or active siRNA (siEGFP). The 
experiments were performed with a fixed NG concentration (30 µg mL-1). Every well contained 5 nM siRNA. 
For the uptake experiments fluorescent siRNA was used (0.75 mol% Cy5-labeled). Data points represent mean 
fluorescence intensities ± standard deviation (n=3). 
 
3.7. Elucidating the intracellular fate of the pulmonary surfactant-coated nanogels 
In order to assess the impact of the pulmonary surfactant outer shell on the intracellular fate of 
the nanoparticles, we performed a colocalization experiment via confocal fluorescence 
microscopy. Here, a specific labeling of the lysosomes was obtained by immunofluorescence 
staining of the lysosomal-associated membrane protein-1 (LAMP-1). H1299 cells were 
incubated with fluorescently labeled siRNA (siCy5) complexed with uncoated nanogels 
(siNGs), coated NGs (coated siNGs-2), or coated NGs-2 incorporating 7.5 wt% DSPE-
PEG2000-folate (coated siNGs-2 folate). The confocal images clearly show a punctuated siCy5 
fluorescence which is indicative of endocytic uptake (Figure 7). The observed differences in 
intracellular siCy5 fluorescence between the formulations confirm our data obtained with 
flow cytometry. Moreover, the images clearly illustrate colocalization of the red-labeled 
nanoparticles and the green-labeled lysosomes. In addition, we performed a detailed 
colocalization analysis using appropriate image processing software. This analysis revealed 
that ~80 % of the siNGs were colocalized with the lysosomes. Importantly, the presence of a 
pulmonary surfactant outer shell, with or without incorporated folate-modified lipids, did not 
significantly alter the extent of lysosomal sequestration. 
 
 
 
Figure 7. Confocal images of fluorescent siRNA (siCy5) complexed with nanogels (siNGs), pulmonary 
surfactant-coated NGs (coated siNGs-2) or coated NGs incorporating 7.5 wt% folate (coated siNGs-2 
folate) in H1299 cells. A specific labeling of lysosomes was obtained by immunofluorescence staining against 
lysosomal-associated membrane protein-1 (LAMP-1). The experiments were performed with a fixed nanogel 
(NG) concentration (30 µg mL-1) complexed with 10 pmol siCy5 per µg NG. Scale bars correspond with 10 µm. 
 
4. Discussion 
 
In this study, we have successfully designed a targeted composite nanocarrier composed of a 
siRNA-loaded dextran nanogel (siNG) core and a pulmonary surfactant shell. Hybrid 
nanoparticles, combining the benefits of both polymer- and lipid-based nanoparticles within a 
single delivery vehicle, have emerged as a promising drug delivery platform [14-16]. A 
number of examples have been described in the literature that highlight the potential of such 
hybrid nanoparticles for siRNA delivery upon systemic application [17, 18]. However, their 
value for pulmonary siRNA delivery was not yet evaluated. In addition, although synthetic 
drug carriers are being actively developed for many applications, a growing interest exists in 
the implementation of bio-inspired materials in drug delivery [22, 23].  
We evaluated two distinct protocols to synthesize surfactant-coated siNGs. Hybrid 
nanoparticles prepared via the coated siNGs-2 protocol (Figure 1b) clearly outperformed the 
nanoparticles prepared via the coated siNGs-1 protocol (Figure 1a) in terms of safeguarding 
the siRNA payload in the presence of a destabilizing agent (i.e. mucin). Likely, the 
electrostatic interaction between the siNGs and preformed Curosurf® vesicles (coated siNGs-
1) does not allow optimal fusion of surfactant lipids on the NG surface, as also evidenced by 
the large shift in hydrodynamic diameter (Figure 2). The observed shift in size will likely 
correspond with the mere electrostatic attachment of surfactant vesicles to the NG surface, 
given the average diameter of ± 80 nm, as measured for the Curosurf® vesicles. The absence 
of an effective fusion of the surfactant vesicles on the NG surface is in contrast with earlier 
reports on mesoporous silica nanoparticles for which incubation with anionic liposomes led to 
spontaneous fusion of the liposomes on the nanoparticle surface [42]. On the other hand, 
coated siNGs-2 nanoparticles, have a hydrodynamic size that more closely resembles the size 
of the original siNG core (Figure 2) and cryo-TEM analysis confirmed the presence of a 
single surfactant bilayer on the NG surface for the majority of nanoparticles (Figure 4). We 
hypothesize that the high-energy sonication provides enough shear force to facilitate lipid 
reorganization around the nanoparticle surface. Nevertheless, the pulmonary surfactant shell 
did not completely block siRNA release from the NG core in the presence of strongly 
negatively charged polymers, such as mucin and dextran sulfate (Figure 3a). This can 
possibly be attributed to defects in the pulmonary surfactant shell, as observed for some 
particles in the cryo-TEM images (Figure S3), allowing the diffusion of the polyanions into 
the NG core and subsequent siRNA displacement.  
The electrostatic interaction between the siNG core and the pulmonary surfactant shell 
appeared to be the predominant factor driving the coating process. This was clearly reflected 
by the inability to prepare stable core-shell nanoparticles in the presence of isotonic salt 
concentrations (Figure 3c). The higher ionic strength, compared to HEPES buffer, enhanced 
the shielding of the surface charges, thereby significantly decreasing the electrostatic 
interaction between the siNGs and pulmonary surfactant. 
In previous work by our group, it was already illustrated that pulmonary surfactant could 
potentiate intracellular siRNA delivery [29]. Importantly, we now demonstrated that by 
integrating the pulmonary surfactant in the design of a core-shell drug delivery formulation, 
its beneficial effects on intracellular siRNA delivery are maintained. We noted a substantial 
decrease in cellular internalization for the hybrid nanoparticle, most likely attributed to the 
negative charge of the pulmonary surfactant outer layer, which reduces the interaction with 
the plasma membrane and therefore precludes efficient endocytic uptake. Remarkably, despite 
this observation, the coated siNGs-2 achieved the same gene silencing effect than their 
uncoated counterparts (Figure 5). Notably, assessing the intracellular fate of the nanoparticles 
via fluorescence colocalization analysis did not reveal any obvious differences in intracellular 
trafficking as both coated and uncoated formulations showed equal accumulation in LAMP-1 
stained lysosomes (Figure 7). The elucidation of the exact mechanism via which the 
pulmonary surfactant promotes cytosolic siRNA delivery will likely require a more detailed 
investigation.  
Given the substantial reduction in intracellular siRNA dose due to the presence of a protective 
outer layer, it can be postulated that the efficacy of our hybrid nanoparticle could be further 
enhanced by incorporating an active targeting ligand that drives receptor-mediated 
endocytosis. Folate has been widely used as targeting moiety for drug delivery in cancer 
therapy because of its high affinity and specificity for the folate receptor (FR), which is 
frequently overexpressed on the surface of a variety of human tumors [43, 44]. In this study, 
PEGylated lipids carrying a folate group at its distal end (DSPE-PEG2000-folate) were 
incorporated in the pulmonary surfactant bilayer. The presence of PEG chains did not 
interfere with the deposition of a stable pulmonary surfactant shell, given that the inclusion of 
up to 10 wt% DSPE-PEG2000-folate did not influence size or stability of the hybrid 
nanoparticles (Figure S5).  
The presence of the folate targeting ligands clearly guided receptor-mediated cellular 
internalization in lung cancer cells. Moreover, we have identified that a critical surface 
density of folate is required to drive the receptor-mediated internalization process [45]. Most 
importantly, the increase in cellular siRNA dose linearly correlated with an improved RNAi 
effect, achieving a marked gene silencing in lung cancer cells at siRNA concentrations in the 
low nanomolar range. These results also indicate that altering the pulmonary surfactant 
composition by adding up to 10 wt% of PEGylated lipids does not debilitate its delivery-
enhancing properties (Figure 6). 
 
5. Conclusions 
 
Taken together, we have developed a highly efficient, bio-inspired hybrid nanoparticle with 
promising features for siRNA inhalation therapy. The hybrid nanoparticle consists of a 
cationic biodegradable dextran nanogel core that is loaded with siRNA and is layered with a 
pulmonary surfactant shell. We have found that the pulmonary surfactant shell improves the 
stability, potentiates intracellular siRNA delivery and enables the inclusion of targeting 
moieties. To date the instillation of exogenous pulmonary surfactant was solely used as 
standard therapeutic intervention for neonatal respiratory distress syndrome [46]. However, 
research is currently ongoing in order to understand how pulmonary surfactant replacement 
could benefit a wider range of lung diseases, since it was already indicated that pulmonary 
surfactant dysfunction contributes to the development and outcome of several respiratory 
diseases [47, 48]. This implies that our formulation, combining the high transfection 
efficiency of the dextran nanogels with the inherent therapeutic potential of a clinically 
approved pulmonary surfactant, provides new therapeutic opportunities for the treatment of 
lung diseases with underlying pulmonary surfactant dysfunction. 
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